Vivoryon Therapeutics N.V. to Present at Upcoming Conferences

On February 21, 2023 Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, reported that Dr. Ulrich Dauer, CEO of Vivoryon Therapeutics, will present at the following investor conferences and industry events (Press release, Vivoryon Therapeutics, FEB 21, 2023, View Source [SID1234627456]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BioCapital Europe 2023

Date: March 9, 2023

Time: 09:40 am CET

Venue: Hotel Sofitel Legend The Grand Amsterdam; Amsterdam, The Netherlands

Barclays Global Healthcare Conference

Date: March 16, 2023

Time: 08:00 am EDT / 01:00 pm CET

Venue: Loews Miami Beach Hotel; Miami, USA

A webcast of the presentation will be available via the "Presentations & Webcasts" page in the Investor Relations section on the Company’s website at www.vivoryon.com and will be archived on the Company’s website for 30 days following the conference.

German Biotechnology Days (Deutsche Biotechnologietage) 2023

Date: March 29, 2023

Time: 02:00 pm CEST

Venue: RheinMain CongressCenter; Wiesbaden, Germany

Syndax to Announce Fourth Quarter and Year-end 2022 Financial Results and Host Conference Call and Webcast on February 28, 2023

On February 21, 2023 Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, reported that it will report its fourth quarter and year-end 2022 financial results and provide a business update on Tuesday, February 28, after the close of the U.S. financial markets (Press release, Syndax, FEB 21, 2023, View Source [SID1234627455]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In connection with the earnings release, Syndax’s management will host a conference call and live audio webcast at 4:30 p.m. ET on Tuesday, February 28, 2023 to discuss the Company’s financial results and provide a business update.

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company’s website. Alternatively, the conference call may be accessed through the following:

Conference ID: SNDXQ422
Domestic Dial-in Number: 800-245-3047
International Dial-in Number: 203-518-9765
Live webcast: https://www.veracast.com/webcasts/OpenEx/General/SNDXQ4.cfm

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company’s website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.

Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics

On February 21, 2023 Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, reported its preclinical data on SNS-101, a conditionally active, pH-selective VISTA-blocking antibody, in an oral presentation at Next Generation Antibody Therapeutics: From Discovery to Patient, organized by Keystone Symposia (Press release, Sensei Biotherapeutics, FEB 21, 2023, View Source [SID1234627454]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Preclinical studies to date have demonstrated SNS-101’s potential to significantly enhance the anti-tumor effects of PD-1 blockade while abrogating target-mediated drug disposition (TMDD) and with lower risk of cytokine release syndrome (CRS). New crystal structure analysis further elucidates the antibody’s mechanism of action, showing that SNS-101 directly blocks the pH-dependent interaction between VISTA and PSGL-1," said Edward van der Horst, Ph.D., Chief Scientific Officer of Sensei Biotherapeutics. "Together, these preclinical data support the biological rationale for our pH-dependent approach, which we believe is key to targeting active protonated VISTA with exquisite selectivity."

Presentation highlights:

The epitope of SNS-101 was determined by co-crystallization of VISTA with the fragment antigen-binding domain of SNS-101. Crystal structure analysis suggests SNS-101 directly blocks the pH-dependent interaction between VISTA and PSGL-1, as well as interactions with other putative receptors.
In vitro and in vivo assays demonstrated that treatment with SNS-101 potentially has a significantly lower risk of inducing CRS than a non-pH-dependent VISTA antibody.
SNS-101 exhibited linear elimination kinetics in non-human primates, overcoming TMDD-induced pharmacokinetic limitations observed with other anti-VISTA antibodies.
SNS-101 induced expansion of naïve and memory T-cell phenotypes in vivo without activation or depletion of monocytes, differentiating it from non-pH-selective antibodies.
SNS-101 demonstrated significant enhancement of anti-tumor effects in combination with anti-PD-1 antibodies in syngeneic tumor models.
Sensei expects to submit an Investigational New Drug (IND) application for SNS-101 in or before April 2023, with a Phase 1/2 clinical trial expected to commence in 2023, pending regulatory clearance.

A poster summarizing content from Dr. van der Horst’s oral presentation will be on display at the conference during Poster Session 2, being held today, February 21, 2023, at 7:30 p.m. MST. The poster will be available on the Sensei website following the poster session.

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023

On February 21, 2023 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, reported that it will report financial results for the fourth quarter and full year 2022 on Monday, February 27, 2023, after market close (Press release, Revolution Medicines, FEB 21, 2023, View Source [SID1234627453]). At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and full year, and provide an update on corporate progress.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To listen to the live webcast, or access the archived webcast, please visit: View Source Following the live webcast, a replay will be available on the company’s website for at least 14 days.

PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

On February 21, 2023 PTC Therapeutics, Inc. (NASDAQ: PTCT) reported a corporate update and financial results for the fourth quarter and full year ending December 31, 2022 (Press release, PTC Therapeutics, FEB 21, 2023, View Source [SID1234627452]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"2023 will be a very exciting year at PTC, including a celebration of our 25th anniversary," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "Together our marketed products grew 30% in revenue in 2022 despite significant foreign exchange headwinds. We expect our revenue growth to accelerate further in 2023, potentially reaching $1 billion in total revenue. We are also advancing a broad and deep pipeline of new therapies that we expect to provide substantial growth in the coming years."

Key Corporate Updates:

2022 total revenue of $699 million, representing 30% year-over-year growth, or $740 million when calculated at CER, representing a 37% growth
2022 revenue for the Duchenne muscular dystrophy (DMD) franchise was $507 million, representing 20% year-over-year growth, or $539 million when calculated at CER, representing a 27% growth. The DMD franchise fourth quarter total net product revenue was $114 million
Translarna (ataluren) total net product revenue was $56 million, with growth coming from new patients in existing geographies and continued geographic expansion
Emflaza (deflazacort) total net product revenue was $58 million, driven by new patient starts, broader access, continued high compliance, and appropriate weight-based dosing
Key Clinical and Regulatory Updates:

PTC continues to make progress in additional ongoing registration-directed clinical studies:
The APHENITY Phase 3 trial of sepiapterin (PTC923) for PKU, with results anticipated in May 2023
The MIT-E Phase 2/3 vatiquinone trial for mitochondrial disease associated seizures, with results anticipated in the second quarter of 2023
The MOVE-FA Phase 3 vatiquinone trial for Friedreich ataxia, with results anticipated in the second quarter of 2023
Enrollment in the PIVOT-HD Phase 2 trial of PTC518 for Huntington’s disease is active and ongoing at study sites in Europe and Australia. Data from the first 12 weeks of the placebo-controlled trial is anticipated in the second quarter of 2023.
Fourth-Quarter and Full-Year 2022 Financial Highlights:

Total revenues were $167.4 million for the fourth quarter of 2022, compared to $165.2 million for the fourth quarter of 2021. Total revenues were $698.8 million for the full year 2022, compared to $538.6 million for the full year 2021.
Total revenue includes net product revenue across the commercial portfolio of $127.5 million for the fourth quarter of 2022 and $535.2 million for the full year 2022, compared to $118.9 million for the fourth quarter of 2021 and $428.9 million for the full year 2021. Total revenue also includes collaboration and royalty revenue of $39.9 million in the fourth quarter of 2022 and $163.6 million for the full year 2022, compared to $46.3 million for the fourth quarter of 2021 and $109.7 million for the full year 2021.
Translarna net product revenues were $55.8 million for the fourth quarter of 2022, compared to $69.7 million for the fourth quarter of 2021. Translarna net product revenues were $288.6 million for the full year 2022, compared to $236.0 million for the full year 2021. These results were driven by treatment of new patients, continued high compliance, and geographic expansion.
Emflaza net product revenues were $58.1 million for the fourth quarter of 2022, compared to $47.5 million for the fourth quarter of 2021. Emflaza net product revenues were $218.3 million for the full year 2022, compared to $187.3 million for the full year 2021. These results reflect new patient prescriptions, high compliance, and fewer discontinuations.
Roche reported Evrysdi 2022 year to date sales of approximately CHF 1,119 million, resulting in full year 2022 royalty revenue of $113.5 million to PTC, as compared to $54.6 million for full year 2021.
Based on U.S. GAAP (Generally Accepted Accounting Principles), GAAP R&D expenses were $188.7 million for the fourth quarter of 2022, compared to $149.8 million for the fourth quarter of 2021. GAAP R&D expenses were $651.5 million for the full year 2022, compared to $540.7 million for the full year 2021. The increase reflects additional investment in research programs and advancement of the clinical pipeline.
Non-GAAP R&D expenses were $174.7 million for the fourth quarter of 2022, excluding $14.0 million in non-cash, stock-based compensation expense, compared to $136.4 million for the fourth quarter of 2021, excluding $13.4 million in non-cash, stock-based compensation expense. Non-GAAP R&D expenses were $595.6 million for the full year 2022, excluding $55.9 million in non-cash, stock-based compensation expense, compared to $487.1 million for the full year 2021, excluding $53.6 million in non-cash, stock-based compensation expense.
GAAP SG&A expenses were $92.7 million for the fourth quarter of 2022, compared to $86.5 million for the fourth quarter of 2021. GAAP SG&A expenses were $326.0 million for the full year 2022, compared to $285.8 million for the full year 2021. The increase reflects our continued investment to support commercial activities, including expanding our commercial portfolio.
Non-GAAP SG&A expenses were $79.3 million for the fourth quarter of 2022, excluding $13.4 million in non-cash, stock-based compensation expense, compared to $73.7 million for the fourth quarter of 2021, excluding $12.8 million in non-cash, stock-based compensation expense. Non-GAAP SG&A expenses were $271.5 million for the full year 2022, excluding $54.5 million in non-cash, stock-based compensation expense, compared to $235.9 million for the full year 2021, excluding $49.9 million in non-cash, stock-based compensation expense.
Intangible asset impairment was $33.4 million for the fourth quarter and full year 2022, which represents a non-cash charge. The partial impairment was related to a decrease in projected cash flows due to refinements in current market assumptions and the timing of patient treatments.
Change in the fair value of deferred and contingent consideration was a loss of $6.3 million for the fourth quarter of 2022, compared to a gain of $12.1 million for the fourth quarter of 2021. Change in the fair value of deferred and contingent consideration was a gain of $25.9 million for the full year 2022, compared to a gain of $0.5 million for the full year 2021. The change in fair value of deferred and contingent consideration is related to the fair valuation of potential future consideration to be paid to former equity holders of Agilis Biotherapeutics, Inc. (Agilis) in connection with PTC’s acquisition of Agilis, which closed in August 2018.
Net loss was $170.9 million for the fourth quarter of 2022, compared to net loss of $143.3 million for the fourth quarter of 2021. Net loss was $559.0 million for the full year 2022, compared to net loss of $523.9 million for the full year 2021.
Cash, cash equivalents, and marketable securities was $410.7 million at December 31, 2022, compared to $773.4 million at December 31, 2021.
Shares issued and outstanding as of December 31, 2022, were 73,104,692.
PTC Reaffirms Full Year 2023 Financial Guidance:

PTC anticipates total revenues for the full year 2023 to be between $940 million and $1.0 billion.
PTC anticipates net product revenues for the DMD franchise for the full year 2023 to be between $545 million and $565 million.
PTC anticipates GAAP R&D and SG&A expense for the full year 2023 to be between $1.01 billion and $1.06 billion.
PTC anticipates Non-GAAP R&D and SG&A expense for the full year 2023 to be between $890 million and $940 million, excluding estimated non-cash, stock-based compensation expense of $120 million. PTC anticipates up to $80 million of one-time payments upon achievement of potential clinical and regulatory success-based milestones from previous acquisitions.
Non-GAAP Financial Measures:

In this press release, the financial results of PTC are provided in accordance with GAAP and using certain non-GAAP financial measures. In particular, the non-GAAP R&D and SG&A expense financial measures exclude non-cash, stock-based compensation expense, and the revenue and percentage changes in revenue growth at CER are presented excluding the impact of changes in foreign currency exchange rates. For financial measures given at CER, the current period’s foreign currency revenue values are converted into U.S. dollars using the average exchange rates from the prior period. These non-GAAP financial measures are provided as a complement to financial measures reported in GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management’s opinion, these non-GAAP financial measures are useful to investors and other users of PTC’s financial statements by providing greater transparency into the historical and projected operating performance of PTC and the company’s future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. Quantitative reconciliations of the non-GAAP financial measures to their respective closest equivalent GAAP financial measures are included in the table below.

PTC Therapeutics, Inc.
Consolidated Statements of Operations
(In thousands, except share and per share data)

Three Months Ended
December 31,

Twelve Months Ended
December 31,

2022

2021

2022

2021

Revenues:

Net product revenue

$

127,508

$

118,905

$

535,228

$

428,904

Collaboration revenue

28

25,029

50,052

55,046

Royalty revenue

39,876

21,294

113,521

54,643

Total revenues

167,412

165,228

698,801

538,593

Operating expenses:

Cost of product sales, excluding amortization of acquired intangible assets

10,893

9,327

44,678

32,328

Amortization of acquired intangible asset

35,764

16,340

116,554

54,751

Research and development (1)

188,694

149,844

651,496

540,684

Selling, general and administrative (2)

92,718

86,548

325,998

285,773

Intangible asset impairment

33,384

33,384

Change in the fair value of deferred and contingent consideration

6,300

(12,100)

(25,900)

(500)

Total operating expenses

367,753

249,959

1,146,210

913,036

Loss from operations

(200,341)

(84,731)

(447,409)

(374,443)

Interest expense, net

(24,500)

(22,502)

(90,871)

(86,022)

Other income (expense), net

35,147

(31,375)

(49,207)

(57,875)

Loss before income tax expense

(189,694)

(138,608)

(587,487)

(518,340)

Income tax benefit (expense)

18,805

(4,657)

28,470

(5,561)

Net loss attributable to common stockholders

$

(170,889)

$

(143,265)

$

(559,017)

$

(523,901)

Weighted-average shares outstanding:

Basic and diluted (in shares)

72,656,790

70,669,797

71,728,634

70,466,393

Net loss per share—basic and diluted (in dollars per share)

$

(2.35)

$

(2.03)

$

(7.79)

$

(7.43)

(1) Research and development reconciliation

GAAP research and development

$

188,694

$

149,844

$

651,496

$

540,684

Less: share-based compensation expense

13,973

13,416

55,869

53,632

Non-GAAP research and development

$

174,721

$

136,428

$

595,627

$

487,052

(2) Selling, general and administrative reconciliation

GAAP selling, general and administrative

$

92,718

$

86,548

$

325,998

$

285,773

Less: share-based compensation expense

13,370

12,819

54,464

49,881

Non-GAAP selling, general and administrative

$

79,348

$

73,729

$

271,534

$

235,892

PTC Therapeutics, Inc.

Reconciliation of GAAP to Non-GAAP Revenue and Year-Over-Year Revenue Growth at Constant Exchange Rates

(In thousands, except percentages)

December 31, 2022

December 31, 2022

Twelve Months Ended

Twelve Months Ended

GAAP DMD revenue as reported; GAAP year-over-year revenue growth

$

506,846

20 %

Impact of foreign currency translation – DMD net product revenue; year-over year DMD net product revenue growth

32,300

7 %

Non-GAAP DMD revenue at constant exchange rate; Non-GAAP year-over-year revenue growth at constant exchange rate

$

539,146

27 %

December 31, 2022

December 31, 2022

Twelve Months Ended

Twelve Months Ended

GAAP total revenue as reported; GAAP year-over-year

total revenue growth

$

698,801

30 %

Total impact of foreign currency translation – total revenue; year-

over-year total revenue growth

40,800

7 %

Non-GAAP total revenue at constant exchange rate; Non-GAAP

year over-year total revenue growth at constant exchange rate

$

739,601

37 %

PTC Therapeutics, Inc.

Summary Consolidated Balance Sheets

(In thousands, except share data)

December 31, 2022

December 31, 2021

Cash, cash equivalents and marketable securities

$

410,705

$

773,376

Total Assets

$

1,705,619

$

1,938,056

Total debt

$

571,722

$

431,434

Total deferred revenue

1,351

Total liability for sale of future royalties

757,886

733,985

Total liabilities

$

2,052,705

$

1,936,618

Total stockholders’ (deficit) equity (73,104,692 and 70,828,226 common shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively)

$

(347,086)

$

1,438

Total liabilities and stockholders’ (deficit) equity

$

1,705,619

$

1,938,056

PTC Therapeutics, Inc.

Reconciliation of GAAP to Non-GAAP Projected Full Year 2023 R&D and SG&A Expense

(In thousands)

Low End of Range

High End of Range

Projected GAAP R&D and SG&A Expense

$

1,010,000

$

1,060,000

Less: projected non-cash, stock-based compensation expense

120,000

120,000

Projected non-GAAP R&D and SG&A expense

$

890,000

$

940,000

Acronyms:
AADC: Aromatic L-amino acid decarboxylase
ALS: Amyotrophic Lateral Sclerosis
CER: Constant Exchange Rate
DMD: Duchenne Muscular Dystrophy
FDA: U.S. Food and Drug Administration
PKU: Phenylketonuria
R&D: Research and Development
SG&A: Selling, General and Administrative
SMA: Spinal Muscular Atrophy
* Revenue and growth at Constant Exchange Rates, or CER, represents revenue and growth calculated as if the exchange rates had remained unchanged from average exchange rates in 2021. CER is a non-GAAP measure.

Today’s Conference Call and Webcast Reminder:

To access the call by phone, please click here to register and you will be provided with dial-in details. To avoid delays, we recommend participants dial in to the conference call 15 minutes prior to the start of the call. The webcast conference call can be accessed on the Investor section of the PTC website at View Source A replay of the call will be available approximately two hours after completion of the call and will be archived on the company’s website for 30 days following the call.